885664-75-5

Upstream product

• 885664-74-4 9-bromo-8-hydroxy-N-phenyl-nonanamide 
• 62-53-3 aniline 
• 31642-67-8 non-8-enoic acid 
• 885664-71-1 7-oxiranyl-heptanoic acid phenylamide 
• 885664-73-3 N-phenyl-8-nonenamide 

Downstream Products

• 948838-21-9 C₁₈H₂₅NO₂S₃ 
• 885664-68-6 thioacetic acid S-(2-oxo-8-phenylcarbamoyl-octyl) ester 

Relevant academic research and scientific papers

Trithiocarbonates-Exploration of a new head group for HDAC inhibitors

Inhibition of histone deacetylases class I/II enzymes is a new, promising approach for cancer therapy. In the present study, we disclose a new structural class of HDAC inhibitors with the trithiocarbonate motif. A clear structure-activity-relationship was obtained for the cap-linker motif and the putative Zn2+ complexing head group. Selected analogs display potent inhibition of HDAC enzymatic activity and a cellular potency comparable to that of suberoylanilide hydroxamic acid (SAHA), recently approved for treatment of patients with advanced cutaneous T-cell lymphoma.

Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases

Suberoylanilide hydroxamic acid (SAHA), an inhibitor of histone deacetylase, is used in clinical trials for a variety of advanced cancers. Twelve new analogs of SAHA were synthesized and tested as in vitro inhibitors of isolated histone deacetylases (HDACS) and in vivo inhibitors of interferon regulated transcriptional responses (a marker for HDAC activity). The analogs containing an α-mercaptoketone or an α-thioacetoxyketone were more potent than SAHA in both assays.